Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia

 
• By Jessica Merrill

The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.

SC1912_Success_325170179_1200.jpg
Aredlyx's tenapanor was successful in a second Phase III trial • Source: Shutterstock

More from Financing

More from Business